9.77
-0.03(-0.31%)
Currency In USD
| Previous Close | 9.8 |
| Open | 9.85 |
| Day High | 10.01 |
| Day Low | 9.48 |
| 52-Week High | 10.38 |
| 52-Week Low | 1.45 |
| Volume | 574,348 |
| Average Volume | 1.27M |
| Market Cap | 713.08M |
| PE | -3.91 |
| EPS | -2.5 |
| Moving Average 50 Days | 8.94 |
| Moving Average 200 Days | 5.19 |
| Change | -0.03 |
If you invested $1000 in Lexeo Therapeutics, Inc. Common Stock (LXEO) since IPO date, it would be worth $972.14 as of December 14, 2025 at a share price of $9.77. Whereas If you bought $1000 worth of Lexeo Therapeutics, Inc. Common Stock (LXEO) shares 1 year ago, it would be worth $1,379.94 as of December 14, 2025 at a share price of $9.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
GlobeNewswire Inc.
Dec 04, 2025 1:00 PM GMT
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, “A C
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
GlobeNewswire Inc.
Oct 20, 2025 8:05 PM GMT
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previo
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
GlobeNewswire Inc.
Oct 17, 2025 3:29 AM GMT
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its underwritten